PunjiPUNJI
Pharmaceuticals & BiotechnologySmall Cap

Morepen Laboratories Ltd.

MOREPENLAB · ISIN: INE083A01026

Morepen Laboratories Ltd. is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE083A01026.

Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.

Close (as of 2026-10-29)
₹119.31
-4.99% today
Day Range
₹119.31 - ₹119.31
Market Cap (Small Cap)
₹6,537.635 Cr
Quality Score (as of 2026-09-30)
53.3/100

Price History

CHART

Morepen Laboratories Ltd. - growth of ₹100

Growth of ₹100 invested on 2021-11-30, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.

-29571432293152021-11-302023-11-302025-02-012025-07-252026-01-162026-07-102026-08-312026-10-062026-10-29

1M

-5.3%

3M

+109.17%

6M

+188.47%

1Y

+144.29%

3Y CAGR

+52.94%

5Y CAGR

-

Earnings (TTM)

LEARN: Revenue and PAT · EPS · P/E

CHART

Morepen Laboratories Ltd. - revenue & profit (TTM)

Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-09-30.

0 Cr640 Cr1280 Cr1920 Cr2560 CrQ3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027Q2 FY2027
Revenue (TTM)PAT (TTM)

11.73%

EBITDA Margin (TTM)

Technicals

117.19

SMA (50)

146.3%

1Y Return

154.1084

Avg Traded Value (20D, ₹Cr)

As of 2026-10-29.

Shareholding Pattern

CHART

Shareholding by category

As of 2026-09-30.

35.65%64.35%TOP 2100%
Promoter 35.65%Public 64.35%

Corporate Actions

No corporate actions on record for this stock.

Recent Deals

DateTypeQuantity
2026-10-22SHORT_SELL19
2026-10-21SHORT_SELL2
2026-10-13SHORT_SELL419
2026-09-16BULK28,13,508
2026-09-16BULK25,28,438
2026-09-09SHORT_SELL1
2026-09-07SHORT_SELL200
2026-09-01SHORT_SELL31
2026-08-31BULK31,76,302
2026-08-31BULK31,84,756
2026-08-18SHORT_SELL6,000
2026-08-17BULK36,72,287
2026-08-17BULK41,27,672
2026-08-17SHORT_SELL101
2026-08-14SHORT_SELL24,573
2026-08-13SHORT_SELL1
2026-08-13BULK32,56,549
2026-08-13BULK28,27,296
2026-08-06BULK28,27,626
2026-08-06BULK53,20,163

Frequently asked questions

What is Morepen Laboratories Ltd.'s 1-year and 3-year return?

Morepen Laboratories Ltd.'s 1-year price return is +144.29%. Its 3-year CAGR (annualized return) is +52.94%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.

What is Morepen Laboratories Ltd.'s latest financial performance?

Morepen Laboratories Ltd.'s trailing-twelve-month (TTM) revenue as of 2026-09-30 is ₹2,286 Cr, with a TTM profit after tax of ₹189 Cr and an EBITDA margin of 11.73%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹3.43, with a 5-year EPS growth rate of 7.4% - a rough proxy for how consistently the company has grown per-share earnings over a full market cycle.

What is Morepen Laboratories Ltd.'s quality score?

Morepen Laboratories Ltd. has a Punji quality score of 53.3 out of 100 as of 2026-09-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.

What do Morepen Laboratories Ltd.'s technical indicators show?

As of 2026-10-29, Morepen Laboratories Ltd.'s RSI (14-day) is 47.29 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.

Who are the major shareholders of Morepen Laboratories Ltd.?

As of 2026-09-30, Morepen Laboratories Ltd.'s shareholding is split across Promoter (35.65%), Public (64.35%). Promoter holding of 35.65% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.

Has Morepen Laboratories Ltd. seen any recent bulk or block deals?

Yes, as of 2026-10-22 - the most recent recorded deal was a SHORT_SELL on 2026-10-22 for 19 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.

Stock data · Not financial advice · Past performance does not indicate future returns